首页> 美国卫生研究院文献>Autophagy >Research Article: Q6 a novel hypoxia-targeted drug regulates hypoxia-inducible factor signaling via an autophagy-dependent mechanism in hepatocellular carcinoma
【2h】

Research Article: Q6 a novel hypoxia-targeted drug regulates hypoxia-inducible factor signaling via an autophagy-dependent mechanism in hepatocellular carcinoma

机译:研究文章:Q6一种针对缺氧的新型药物通过自噬依赖性机制调节肝细胞癌中的缺氧诱导因子信号传导

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tumor hypoxia underlies treatment failure and yields more aggressive and metastatic cancer phenotypes. Although therapeutically targeting these hypoxic environments has been proposed for many years, to date no approaches have shown the therapeutic value to gain regulatory approval. Here, we demonstrated that a novel hypoxia-activated prodrug, Q6, exhibits potent antiproliferative efficacy under hypoxic conditions and induces caspase-dependent apoptosis in 2 hepatocellular carcinoma (HCC) cell lines, with no obvious toxicity being detected in 2 normal liver cell lines. Treatment with Q6 markedly downregulated HIF1A [hypoxia inducible factor 1, α subunit (basic helix-loop-helix transcription factor)] expression and transcription of the downstream target gene, VEGFA (vascular endothelial growth factor A). This dual hypoxia-targeted modulation mechanism leads to high potency in suppressing tumor growth and vascularization in 2 in vivo models. Intriguingly, it is the autophagy-dependent degradation pathway that plays a crucial role in Q6-induced attenuation of HIF1A expression, rather than the proteasome-dependent pathway, which is normally regarded as the predominant mechanism underlying posttranslational regulation of HIF1A. Inhibition of autophagy, either by short interfering RNA (siRNA) or by chemical inhibitors, blocked Q6-induced HIF1A degradation. Autophagic degradation of HIF1A was further confirmed by the observation that HIF1A coimmunoprecipitated with the ubiquitin-binding adaptor protein, SQSTM1, which is degraded through autophagy. Additionally, silencing of SQSTM1 inhibited Q6-induced HIF1A degradation. These findings suggest that the novel hypoxia-targeted agent, Q6, has potential clinical value in the therapy of HCC. Furthermore, the identification of autophagy as a crucial regulator of HIF1A provides new insights into hypoxia-related treatments.
机译:肿瘤缺氧是治疗失败的基础,并产生更具侵略性和转移性的癌症表型。尽管已经提出了针对这些低氧环境的治疗性疗法,但迄今为止,尚无任何方法显示出获得监管机构批准的治疗性价值。在这里,我们证明了一种新型的缺氧激活前药Q6在低氧条件下表现出强大的抗增殖功效,并在2种肝细胞癌(HCC)细胞系中诱导了caspase依赖性凋亡,而在2种正常肝细胞系中均未检测到明显的毒性。 Q6处理显着下调了HIF1A [低氧诱导因子1,α亚基(基本螺旋-环-螺旋转录因子)]的表达和下游靶基因VEGFA(血管内皮生长因子A)的转录。这种双重靶向低氧的调节机制在2个体内模型中均具有抑制肿瘤生长和血管形成的高效能。有趣的是,自噬依赖性降解途径在Q6诱导的HIF1A表达减弱中起着关键作用,而不是蛋白酶体依赖性途径,后者通常被认为是HIF1A翻译后调控的主要机制。通过短干扰RNA(siRNA)或化学抑制剂抑制自噬,可以阻止Q6诱导的HIF1A降解。通过观察到HIF1A与泛素结合衔接蛋白SQSTM1共免疫沉淀而进一步证实了HIF1A的自噬降解,该蛋白通过自噬被降解。此外,SQSTM1沉默抑制Q6诱导的HIF1A降解。这些发现表明,新型低氧靶向药物Q6在肝癌的治疗中具有潜在的临床价值。此外,自噬作为HIF1A的关键调节因子的鉴定为缺氧相关治疗提供了新的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号